Thank you, Hoff, for this optimistic and apparently realistic regulatory approval scenario.
However, it is just that, a scenario. Unless I missed a press release, we don't actually know if NWBO is taking this approval pathway. We are in the dark. I appreciate your upbeat position, but I must confess to feeling discouraged, frustrated, and anxious due to recent events, esp. in light of info contained (or not contained) in the latest quarterly report.
Discouraged, because like many of you I did not see any sign of revenues from sales of vaccines produced at Sawston, despite a press release from February announcing with great fanfare that production there had begun.
Discouraged, because the quarterly seemed to dash my high hopes, raised by Poor Man, Bright Boy, and others, that the C shares would be sold for more than the market price as a way to wrest pricing power away from unscrupulous market makers who seem to be successful at manipulating the share price to keep it artificially low.
Frustrated and even a little bit hurt/humiliated, because when I wrote a long, courteous email to David Innes, asking for information, guidance, and clarity on half a dozen similar issues, he sent me back, within just a few minutes, a terse response merely stating that a shareholders meeting would be held before the end of the year. He ignored all my other questions, and gave no indication he would ever answer them. So I feel a little stonewalled.
Anxious/fearful since it's clear the company is running out of money, desperate for cash. The burn rate appears to be accelerating, with no sales revenue to even partially offset it. Fortunately Advent appears willing to continue accepting shares in lieu of cash as payment for services, but if I were Advent, I'd begin to wonder if I might be better off selling those shares right away.
Also anxious/fearful due to lack of an employee on staff (and within the top leadership circle) with title of chief medical officer. Clearly, the lack of a CMO is a departure from the norm for small biopharmaceutical companies.
And then the other unanswered question, in my mind, is where on the income statement are the expenses associated with obtaining patent protection in many different foreign countries. You (Hoff), and HenryMuney, Lykiri, and others, have been so very friendly/generous/forthcoming by sharing with us your discoveries of various patents being issued in countries like Israel, Russia, Singapore, Japan, (if memory serves). Last I checked, hiring the services of a patent attorney is not cheap, much less one who works in Tokyo. Where are those expenses being disclosed? Maybe this is a little thing and I shouldn't get too concerned.
In any case, thank you Hoff, for your optimism. Again I agree ILAP looks like it would be a marvelous way for NWBO to go. But it just seems like more wishful thinking. For myself, I feel more like Poor Man just described his feelings: unwilling to extend the company the benefit of the doubt any longer, at least not until they spell out in clear terms what they are doing, what we shareholders can expect. The absence of a press release associated with the C shares -- a corporate announcement of some kind that speaks clearly, plainly, and directly to interested prospective investors -- speaks volumes.
I love the idea of a quarterly earnings call. We can dream, can't we?
-- OncoJock
